SCHEMBL1012855

SCHEMBL1012855

CC(C)OC(=O)CC(=O)CC(=O)OC(C)C

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
TSHR P16473 5/20 0.46
FAAH O00519 4/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
HSD17B10 Q99714 3/20 0.40
ALDH1A1 P00352 3/20 0.40
ALOX15 P16050 1/20 0.40
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP2D6 P10635 1/20 0.37
NLRP3 Q96P20 1/20 0.37
GAA P10253 1/20 0.36
EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6602946 0.91 TSHR (0.44) LMNATSHRFAAHCNR1CNR2
SCHEMBL229792 0.88 TSHR (0.50) LMNATSHRHSD17B10ALDH1A1ALOX15
SCHEMBL29467311 0.87 LMNA (0.47) LMNATSHRFAAHCNR1CNR2
SCHEMBL181911 0.87 LMNA (0.47) LMNATSHRFAAHCNR1CNR2
SCHEMBL11133563 0.87 LMNA (0.42) LMNATSHRFAAHCNR1CNR2
SCHEMBL28727541 0.86 LMNA (0.48) LMNATSHRHSD17B10ALDH1A1ALOX15
SCHEMBL28875912 0.86 LMNA (0.48) LMNATSHRHSD17B10ALDH1A1ALOX15
SCHEMBL18152012 0.86 LMNA (0.48) LMNATSHRHSD17B10ALDH1A1ALOX15
SCHEMBL1037280 0.85 FAAH (0.56) LMNATSHRFAAHCNR1CNR2
SCHEMBL28619359 0.85 LMNA (0.41) LMNATSHRFAAHCNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0033863-A1 Process for the production of cis-bicyclo (3.3.0)octane-3,7-dione, and its use MERCK PATENT GmbH (DE) 1981-08-19 EP claimed
US-20230350299-A1 STEP SUBSTRATE COATING COMPOSITION NISSAN CHEMICAL CORPORATION (JP) 2023-11-02 US disclosed
US-20230244141-A1 PHOTOCURABLE COMPOSITION AND METHOD FOR PRODUCING SEMICONDUCTOR DEVICE NISSAN CHEMICAL CORPORATION (JP) 2023-08-03 US disclosed
US-11681223-B2 Photocurable composition and method for producing semiconductor device NISSAN CHEMICAL CORPORATION (JP) 2023-06-20 US disclosed
US-11674051-B2 Stepped substrate coating composition containing compound having curable functional group NISSAN CHEMICAL CORPORATION (JP) 2023-06-13 US disclosed
US-11454889-B2 Crosslinkable compound-containing photocurable stepped substrate-coating composition NISSAN CHEMICAL CORPORATION (JP) 2022-09-27 US disclosed
US-11385546-B2 Multi-level substrate coating film-forming composition containing plasma-curable compound based on unsaturated bonds between carbon atoms NISSAN CHEMICAL CORPORATION (JP) 2022-07-12 US disclosed
US-11199777-B2 Resist underlayer film-forming composition containing novolac polymer having secondary amino group NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2021-12-14 US disclosed
US-11155684-B2 Photocrosslinkable group-containing composition for coating stepped substrate NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2021-10-26 US disclosed
US-20210024773-A1 STEPPED SUBSTRATE COATING COMPOSITION CONTAINING COMPOUND HAVING CURABLE FUNCTIONAL GROUP NISSAN CHEMICAL CORPORATION (JP) 2021-01-28 US disclosed
US-20070205400-A1 Varnish Containing Good Solvent And Poor Solvent NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2007-09-06 US disclosed
EP-1773102-A1 VARNISH CONTAINING GOOD SOLVENT AND POOR SOLVENT Nissan Chemical Industries, Ltd. (JP) 2007-04-11 EP disclosed
US-20030065183-A1 Process for producing optically active tropinonemonocarboxylic acid ester derivative NIHON MEDI-PHYSICS CO., LTD. 2003-04-03 US disclosed
US-6486323-B1 Process for producing optically active tropinonemonocarboxylic acid derivative NIHON MEDI-PHYSICS CO., LTD. (JP) 2002-11-26 US disclosed
EP-1118674-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE Nihon Medi-Physics Co., Ltd. (JP) 2001-07-25 EP disclosed
EP-0708105-B1 5-HT4 receptor agonists NISSHIN FLOUR MILLING CO (JP) 1998-12-23 EP disclosed
US-5684003-A GASTROINTESTINAL DISORDERS OR ANTIULCER AGENTS NISSHIN FLOUR MILLING CO., LTD. (JP) 1997-11-04 US disclosed
EP-0708105-A1 5-HT4 receptor agonists NISSHIN FLOUR MILLING CO., LTD. (JP) 1996-04-24 EP disclosed
EP-0033863-A1 Process for the production of cis-bicyclo (3.3.0)octane-3,7-dione, and its use MERCK PATENT GmbH (DE) 1981-08-19 EP disclosed
EP-0033863-A1 Process for the production of cis-bicyclo (3.3.0)octane-3,7-dione, and its use MERCK PATENT GmbH (DE) 1981-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065183-A1 Process for producing optically active tropinonemonocarboxylic acid ester derivative CES2, FTO, HAAO LMNA 3458/4885TSHR 2020/4885FAAH 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.